Add to ORKGmortality compared with other oral diabetes drugs or placebo in type 2 diabetes Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “canagliflozin ...
Background—Both diabetes and antidiabetic drugs (ADDs) increase the risk for cardiovascular (CV) dis...
The leading cause of death in type 2 diabetes is cardiovascular disease accounting for an increased ...
cardiovascular outcomes and mortality compared with pioglitazone in type 2 diabetes Loke YK, Kwok CS...
Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for...
Introduction Cardiovascular diseases are the leading cause of morbidity and mortality among individu...
The efects of antihyperglycemic medications on cardiovascular events and mortality are heterogeneous...
Review of: Zheng S, Roddick A, Aghar-Jaffar R, et al. Association between use of sodium-glucose cotr...
AIMS: To investigate cardiovascular disease and mortality trends in control arm participants of diab...
There is a wealth of epidemiological data which shows that type 2 diabetes significantly increase th...
Aims/hypothesis: The aim of this study was to evaluate the risk of adverse cardiovascular outcomes i...
The benefit or risk of sodium glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular (CV) outc...
NOTE: THE SPECIAL CHARACTERS IN THIS ABSTRACT CANNOT BE DISPLAYED CORRECTLY ON THIS PAGE. PLEASE REF...
Aim: To evaluate the risk of all-cause and cardiovascular mortality, acute myocardial infarction, an...
This article is not available through ChesterRep.Type 2 diabetes is associated with an increase in a...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “canagliflozin ...
Background—Both diabetes and antidiabetic drugs (ADDs) increase the risk for cardiovascular (CV) dis...
The leading cause of death in type 2 diabetes is cardiovascular disease accounting for an increased ...
cardiovascular outcomes and mortality compared with pioglitazone in type 2 diabetes Loke YK, Kwok CS...
Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for...
Introduction Cardiovascular diseases are the leading cause of morbidity and mortality among individu...
The efects of antihyperglycemic medications on cardiovascular events and mortality are heterogeneous...
Review of: Zheng S, Roddick A, Aghar-Jaffar R, et al. Association between use of sodium-glucose cotr...
AIMS: To investigate cardiovascular disease and mortality trends in control arm participants of diab...
There is a wealth of epidemiological data which shows that type 2 diabetes significantly increase th...
Aims/hypothesis: The aim of this study was to evaluate the risk of adverse cardiovascular outcomes i...
The benefit or risk of sodium glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular (CV) outc...
NOTE: THE SPECIAL CHARACTERS IN THIS ABSTRACT CANNOT BE DISPLAYED CORRECTLY ON THIS PAGE. PLEASE REF...
Aim: To evaluate the risk of all-cause and cardiovascular mortality, acute myocardial infarction, an...
This article is not available through ChesterRep.Type 2 diabetes is associated with an increase in a...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “canagliflozin ...
Background—Both diabetes and antidiabetic drugs (ADDs) increase the risk for cardiovascular (CV) dis...
The leading cause of death in type 2 diabetes is cardiovascular disease accounting for an increased ...